Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to study the effect - in terms of time to progression and
overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in
subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the
prostate gland.